Skip to content

Journal · Pharmacovigilance · Updated 21 November 2026

Drug Safety

Read Drug Safety articles on DeepDyve. No university library needed.

Drug Safety covers the safety of medicines and vaccines, from adverse drug reactions and pharmacovigilance databases to methods for spotting safety signals. It’s an official journal of the International Society of Pharmacovigilance, published by Springer Nature. It was previously published as Medical Toxicology and Adverse Drug Experience. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Drug Safety
Journal cover

Drug Safety at a glance

Full title
Drug Safety
Former title
Medical Toxicology and Adverse Drug Experience
Abbreviation (NLM)
Drug Saf
Publisher
Springer Nature
Print ISSN
0114-5916
Online ISSN (eISSN)
1179-1942
Current title since
1990
Subjects
Drug Therapy, Toxicology
Access model
Hybrid (56% free to read in 2026)

Ways to access Drug Safety

56% of the articles Drug Safety published from January 1 to November 18, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 56% of Drug Safety articles published from January 1 to November 18, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Drug Safety. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Drug Safety articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Drug Safety’s 2025 Journal Impact Factor is 5.9, and its 5-year Impact Factor is 5.1.

5.9

Journal Impact Factor (2025)

5.1

5-year Impact Factor (2025)

6 days

Median time to first decision

1.2M

Downloads (2025)

Source: journal metrics on the Drug Safety homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Drug Safety research worth reading

Published January to September 2026. Summaries describe what the authors report.

  1. Open accessPharmacovigilance · Databases

    VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines

    Brand and colleagues describe VigiBase, the WHO global database of adverse event reports, which as of 31 December 2024 held over 40 million case reports from over 160 countries, about 80% for medicines and 20% for vaccines.

    Brand et al. · Drug Safety, published online January 30, 2026 · DOI 10.1007/s40264-025-01642-6

  2. Open accessAdverse drug reactions · Anticholinergics

    Unveiling the Limits of Anticholinergic Burden Scales: A Study of Adverse Drug Reactions in the French Pharmacovigilance Database

    In the French pharmacovigilance database, Pecquet and colleagues found 9629 cases with anticholinergic adverse reactions, most often confusion, and report that some drugs involved were missing from, or scored low on, commonly used anticholinergic burden scales.

    Pecquet et al. · Drug Safety, published online January 13, 2026 · DOI 10.1007/s40264-025-01643-5

  3. LitStreamPharmacovigilance · Signal detection

    Theoretical Framework and Key Considerations for Time-to-Onset Analysis in Spontaneous Reporting Systems

    Noguchi and colleagues review time-to-onset analysis in spontaneous reporting databases, arguing it complements disproportionality analysis, and conclude it should serve as an exploratory tool for characterizing onset patterns and generating hypotheses, not to estimate population-level risks or infer causality.

    Noguchi et al. · Drug Safety, published online May 12, 2026 · DOI 10.1007/s40264-026-01677-3

  4. LitStreamPregnancy · Teratogenic drugs

    Risk of Fetal Exposure to Teratogenic Medications: Development of Evidence for the Teratogenic Risk Impact and Mitigation (TRIM) Tool

    In a retrospective US population-based cohort study of Medicaid and MarketScan claims, Wang and colleagues report fetal exposure rates to teratogenic medications ranging from 0 to 1512 per 1000 user-years, with high rates for fluconazole, sulfamethoxazole/trimethoprim, vedolizumab and several anticonvulsants.

    Wang et al. · Drug Safety, published online April 17, 2026 · DOI 10.1007/s40264-026-01653-x

  5. LitStreamAdverse drug reactions · Allopurinol

    Non-genetic Risk Factors for Allopurinol-Induced Severe Cutaneous Adverse Reaction (SCAR): A Systematic Review

    In a systematic review of 26 studies, Ng and colleagues report that female sex, chronic kidney disease and higher allopurinol doses were associated with allopurinol-induced severe cutaneous adverse reactions, while age and concomitant diuretic use were not significantly associated in the primary meta-analyses.

    Ng et al. · Drug Safety, published online September 15, 2026 · DOI 10.1007/s40264-026-01729-8

See every Drug Safety article on DeepDyve

Questions about Drug Safety

How can I read Drug Safety articles without a subscription?

56% of Drug Safety articles published from January 1 to November 18, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Drug Safety articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Drug Safety?

Drug Safety’s NLM (PubMed) abbreviation is Drug Saf.

What is the ISSN of Drug Safety?

The print ISSN is 0114-5916 and the online ISSN is 1179-1942.

What is the impact factor of Drug Safety?

Drug Safety’s Journal Impact Factor is 5.9 (2025), and its 5-year Impact Factor is 5.1, according to Springer Nature’s published metrics.

Is Drug Safety open access?

Drug Safety is a hybrid journal: authors can choose to publish open access or under the subscription model. From January 1 to November 18, 2026, 57 of 102 Drug Safety articles (56%) carry a Creative Commons license, per Crossref.

Drug Safety articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Drug Safety today

One month free, then less than $2 a day. Drug Safety, plus millions of articles from thousands of journals.

Start free month

Like this: